Jazz Phar­ma­ceu­ti­cals gets FDA OK for cat­a­plexy drug as it pre­pares to re­place old cash cow

Fol­low­ing an FDA ap­proval just last month for its small cell lung can­cer drug, Jazz Phar­ma­ceu­ti­cals keeps on rolling.

The Irish phar­ma an­nounced Wednes­day that Xy­wav, treat­ing cat­a­plexy and ex­ces­sive day­time sleepi­ness as­so­ci­at­ed with nar­colep­sy in pa­tients old­er than sev­en years, has been giv­en the green light by US reg­u­la­tors. This is the third FDA ap­proval grant­ed to Jazz in the last 16 months and the sec­ond nar­colep­sy-re­lat­ed drug af­ter Sunosi was OK’ed in March 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.